Department of Transfusion Medicine and Immunohematology, Christian Medical College, Vellore, Tamil Nadu, India.
Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.
Indian J Pathol Microbiol. 2021 Jan-Mar;64(1):117-122. doi: 10.4103/IJPM.IJPM_336_19.
Hemophilia A is classified as mild, moderate, and severe based on Factor VIII levels (FVIII). Clot-based assays only detect initiation of thrombin generation, hence FVIII levels may not accurately predict the bleeding risk in all hemophilia patients. The entire process of thrombin generation as measured by global hemostasis tests like activated partial thromboplastin time clot waveform analysis (APTT CWA) and thrombin generation test (TGT) may reflect the actual bleeding phenotype.
To assess the utility of TGT and CWA as a screening tool to identify bleeders and to evaluate the bleeding phenotype in Hemophilia A.
Prospective, observational study of 147 consecutive patients referred for coagulation workup.
Bleeding assessment tool was used to identify bleeders. Patients were classified as severe and nonsevere bleeders based on clinical criteria. TGT was performed by calibrated automated thrombogram, CWA by photo-optical coagulometer and factor levels by one stage clot-based assays.
The Kruskal-Wallis test with post-hoc analysis was done to examine the difference in CWA/TGT parameters amongst hemophilia classified by FVIII levels. Receiver operating characteristic (ROC) analysis was performed to estimate the diagnostic accuracy of CWA and TGT in discriminating between clinically severe vs nonsevere bleeders.
Using ROC derived cut-offs of min1, min2 and peak height of thrombin (PH), the sensitivity (min1:91.67%, min2:91.67%, PH: 97.22%, FVIII: 86.11%) and specificity (min1:100%, min2:100%, PH: 90.91%, FVIII: 90.91%) of CWA/TGT was superior to FVIII to distinguish between clinically severe vs nonsevere bleeders. Phenotypic heterogeneity of bleeding severity was identified in our study population. Clinical severity correlated with CWA/TGT parameters instead of FVIII levels.
CWA and TGT are more effective tools than conventional factor assays to identify clinically severe bleeders and tailor prophylaxis as per bleeding phenotype.
根据因子 VIII 水平(FVIII),血友病 A 分为轻度、中度和重度。基于凝血的检测仅检测凝血酶生成的起始,因此 FVIII 水平可能无法准确预测所有血友病患者的出血风险。通过激活部分凝血活酶时间凝块波形分析(APTT CWA)和凝血酶生成试验(TGT)等整体止血检测来测量的整个凝血酶生成过程可能反映实际的出血表型。
评估 TGT 和 CWA 作为识别出血者和评估血友病 A 出血表型的筛查工具的效用。
对 147 例连续转诊进行凝血检查的患者进行前瞻性、观察性研究。
使用出血评估工具来识别出血者。根据临床标准,患者分为重度和非重度出血者。通过校准自动血栓图进行 TGT,通过光电凝血仪进行 CWA,通过一步法基于凝血的检测进行因子水平检测。
使用 Kruskal-Wallis 检验和事后分析来检查根据 FVIII 水平分类的血友病患者之间 CWA/TGT 参数的差异。进行接收者操作特征(ROC)分析以估计 CWA 和 TGT 在区分临床严重与非严重出血者方面的诊断准确性。
使用 ROC 衍生的 min1、min2 和凝血酶峰值高度(PH)的截断值,CWA/TGT 的敏感性(min1:91.67%,min2:91.67%,PH:97.22%,FVIII:86.11%)和特异性(min1:100%,min2:100%,PH:90.91%,FVIII:90.91%)优于 FVIII 来区分临床严重与非严重出血者。在我们的研究人群中发现了出血严重程度的表型异质性。临床严重程度与 CWA/TGT 参数相关,而与 FVIII 水平无关。
CWA 和 TGT 是比传统因子检测更有效的工具,可用于识别临床严重出血者,并根据出血表型量身定制预防措施。